Vicasinabin

Overview

Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC 50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R . Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Cannabinoid Receptor

Product Information

• Catalog No.: HY-145604
• CAS No.: 1433361-02-4
• Molecular Formula: C15H22N10O
• Molecular Weight: 358.40
• Purity: 98.32%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (5.80 mM); Clear solution
• Availability: In-stock

Source

Original product source